Edit

Genome Engineering: CRISPR/Cas from Cells to Mice – Virtual – Course and Conference Office

EMBL Course

Genome Engineering: CRISPR/Cas from Cells to Mice – Virtual

Overview
Speakers, Trainers and Organisers
Programme

Course Overview

This course will provide training in genome editing and cell engineering in mammalian cells and mouse embryos using the highly efficient CRISPR/Cas9 system. Participants will learn design of CRISPR targets using bioinformatics tools, generation of gene knock-outs/knock-ins, and target validation using the most current technologies. The course will be split into two groups (mammalian cells OR mice) based on participants’ expertise.

Please note that all participants are expected to engage in all sessions. Particpants should plan for approximately 1 hour extra per day for self paced learning modules.

Audience

This course is aimed at researchers who are familiar with basic molecular and cell biology techniques and who want to learn how to create an engineered mammalian cell line or mouse model using the most recent and advanced CRISPR/Cas9 system. No previous experience in genome editing is required.

Modules/Resources

During this course you will learn:

How to design target specific CRISPR/Cas9 tools
Generation of guide RNA (gRNA)
Transfection optimisation for efficient gene editing
Generation of knock-out and knock-in cell lines and mouse embryos
Validation of genome-edited cell lines and embryos

Learning Outcomes

After this course you should be able to:

Design CRISPR based editing tools for your target gene of interest
Choose the right format of gene editing tool and delivery strategy for your cell type or embryos
Edit, screen and validate the engineered models, embryo manipulation

What Past Participants Say about the Course

“This course is very helpful even for beginners to overcome the barrier and access to CRISPR technique.” – Seungmin Han, WT-CRUK Gurdon Institute, UK

“The EMBL Genome Engineering course provided me with knowledge, confidence and inspiration to use CRISPR/Cas technology.” – Marina Kazantseva, University of Otago, New Zealand